Let’s take 3Q21 first. Mavyret sales for the first half of calendar 2021 were $857M, and 50% of that (the base for calculating ENTA’s royalty rate) is roughly $430M. Hence, $140M of Mavyret sales during 3Q21 ($70M of the royalty base) will pay ENTA at the 10% tier and the remaining (roughly) $290M of 3Q21 Mavyret sales ($145 of the royalty base) will pay ENTA at the 12% tier.
Now, let’s take 4Q21. Mavyret sales for the first three quarters of calendar 2021 were $1.28B, and 50% of that (the base for calculating ENTA’s royalty rate) is $640M. Thus, the first $220M of 4Q21 Mavyret sales ($110M of the royalty base) will be at the 12% tier, and the remainder of 4Q21 Mavyret sales will be at the 14% tier.
According to ABBV’s updated full-year 2021 guidance of $1.7B Mavyret sales ($850M royalty base), the 17% royalty tier will not be reached during calendar 2021.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.